Abstract
Tachykinins (TKs) and their receptors (NK1, NK2 and NK3), which are diffusely expressed in the human gastrointestinal tract, represent an endogenous modulator system regulating enteric secretomotor functions, inflammatory and immune responses, and visceral hypersensitivity, mainly during pathological gut diseases. Pathophysiological implications of TKs in the digestive tract include changes in TK innervation, in the expression of TKs and TK receptors, which result in inflammation- and immune-induced disturbances of gut functions, such as dysmotility (diarrhoea/constipation), secretory diarrhoea and visceral hyperalgesia. Increasing evidence correlates all these TKergic system abnormalities with gastrointestinal diseases of different etiology (i.e. inflammatory bowel diseases, irritable bowel syndrome). Accordingly, TK receptors have been identified as novel targets for the development of new therapeutic agents for clinical use. Available preclinical findings have shown that TK antagonists could counteract the most significant symptoms characterizing these gut diseases.
Keywords: neurokinin A, peristalsis, immunoreactivity, idiopathic chronic constipation, pyloric sphincter, Irritable bowel syndrome
Current Drug Targets
Title: Tachykinins: Role in Human Gastrointestinal Tract Physiology and Pathology
Volume: 7 Issue: 8
Author(s): Giovanna Improta and Maria Broccardo
Affiliation:
Keywords: neurokinin A, peristalsis, immunoreactivity, idiopathic chronic constipation, pyloric sphincter, Irritable bowel syndrome
Abstract: Tachykinins (TKs) and their receptors (NK1, NK2 and NK3), which are diffusely expressed in the human gastrointestinal tract, represent an endogenous modulator system regulating enteric secretomotor functions, inflammatory and immune responses, and visceral hypersensitivity, mainly during pathological gut diseases. Pathophysiological implications of TKs in the digestive tract include changes in TK innervation, in the expression of TKs and TK receptors, which result in inflammation- and immune-induced disturbances of gut functions, such as dysmotility (diarrhoea/constipation), secretory diarrhoea and visceral hyperalgesia. Increasing evidence correlates all these TKergic system abnormalities with gastrointestinal diseases of different etiology (i.e. inflammatory bowel diseases, irritable bowel syndrome). Accordingly, TK receptors have been identified as novel targets for the development of new therapeutic agents for clinical use. Available preclinical findings have shown that TK antagonists could counteract the most significant symptoms characterizing these gut diseases.
Export Options
About this article
Cite this article as:
Improta Giovanna and Broccardo Maria, Tachykinins: Role in Human Gastrointestinal Tract Physiology and Pathology, Current Drug Targets 2006; 7 (8) . https://dx.doi.org/10.2174/138945006778019354
DOI https://dx.doi.org/10.2174/138945006778019354 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Microglia:Neuroprotective and Neurotrophic Cells in the Central Nervous System
Current Drug Targets - Cardiovascular & Hematological Disorders Pathogens and Chronic or Long-Term Neurologic Disorders
Cardiovascular & Hematological Disorders-Drug Targets Role of Granulocyte-colony Stimulating Factor in the Protection of Cerebral Vascular Endothelium, White Matter, and Cognition
Current Neurovascular Research The Endocannabinoid/Endovanilloid System and Depression
Current Neuropharmacology Novel Cardiovascular Risk Factors and Macrovascular and Microvascular Complications of Diabetes
Current Drug Targets Adenosine and Related Drugs in Brain Diseases: Present and Future in Clinical Trials
Current Topics in Medicinal Chemistry Neurotoxic and Neuroactive Compounds from Cnidaria: Five Decades of Research….and More
Central Nervous System Agents in Medicinal Chemistry Monoamine Receptors and Signal Transduction Mechanisms in Suicide
Current Psychiatry Reviews Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Nocistatin: Milestone of One Decade of Research
Current Pharmaceutical Design VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets Functional Neuroanatomy of the Noradrenergic Locus Coeruleus: Its Roles in the Regulation of Arousal and Autonomic Function Part I: Principles of Functional Organisation
Current Neuropharmacology Alpha7 Neuronal Nicotinic Receptor: A Pluripotent Target for Diseases of the Central Nervous System
CNS & Neurological Disorders - Drug Targets Immunological Disturbances and Neuroimaging Findings in Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD) Comorbid Patients
Current Topics in Medicinal Chemistry Current Advances on Different Kinases Involved in Tau Phosphorylation, and Implications in Alzheimers Disease and Tauopathies
Current Alzheimer Research Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology Targeting the Microglial Signaling Pathways: New Insights in the Modulation of Neuropathic Pain
Current Medicinal Chemistry The Role of Oxidative Stress in Depressive Disorders
Current Pharmaceutical Design Pharmacogenomics of Antidepressant Drugs: Focus on Key Findings and Future Directions
Current Pharmacogenomics and Personalized Medicine